Skip to main content
Log in

Phase II Trial of Cisplatin Plus Temozolomide, in Recurrent and Progressive Malignant Glioma Patients

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

We report a phase II trial of cisplatinum and temozolomide (TMZ) combination in recurrent malignant glioma patients. The DNA repair protein O(6)-alkylguanine-DNA alkyltransferase (AGAT) is important in glioblastoma resistance to alkylating antitumor agents. In vitro, cisplatin (CDDP) decreases MGMT activity in a time- and dose-dependent manner. Thirty-three recurrent malignant glioma patients (20 GBM-13 AA) were treated at recurrence or progression with a CDDP and TMZ association. On days 1 and 2, iv CDDP (40 mg/sqm) was administered. TMZ (at the dose of 200 mg/sqm) was administered as a single oral daily-dose on days 2–6 (starting 24 h after the first CDDP dose), the cycle was repeated every 4 weeks. All patients had been previously treated with surgery followed by radiotherapy and CDDP + BCNU chemotherapy. The primary endpoint of the study was progression free survival at 6 months (PFS-6). Secondary endpoints included radiological response and toxicities. Thirty-three patients received a total of 113 courses (median 3 range 1–11). Complete responses were not observed, partial responses were 18.8% with an additional 39.9% of stable disease. For the whole group of patients the PFS at 6 and 12 months was 52% and 15% with a median TTP of 33 weeks. PFS-6 for GBM and Anaplastic astrocytoma (AA) were 35% and 69%, respectively. PFS-12 for GBM and AA were 13.8% and 17.3%, respectively. Median TTP was 21.3 and 39.5 weeks, respectively. The principal toxic effects of the regimen were: neutropenia (5 WHO grade IV), thrombocytopenia (4 WHO grade IV), nausea and vomiting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Tatter SB: Recurrent malignant glioma in adults. Curr Treat Options Oncol 3: 509-524, 2002

    Google Scholar 

  2. Voynov G, Kaufman S, Hong T, Pinkerton A, Simon R, Dowsett R: Treatment of recurrent malignant gliomas with stereotactic intensity modulated radiation therapy. Am J Clin Oncol 25: 606-611, 2002

    Google Scholar 

  3. Trippoli S, Pelagotli F, Wessori A, Vacca F, Vaiani M, Maltoni S: Survival of patients with recurrent malignant glioma treated with Temozolomide: a retrospective observational study. Drugs RD 4: 285-291, 2003

    Google Scholar 

  4. Macdonald DR: Temozolomide for recurrent high-grade glioma. Semin Oncol 28: 3-12, 2001

    Google Scholar 

  5. Dinnes J, Cave C, Huang S, Milne R: A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma. Br J Cancer 86: 499-500, 2002

    Google Scholar 

  6. Spence AM, Berger MS, Livingston RB, Ali-Osman F, Griffin B: Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure. J Neuro-Oncol 2: 187-191, 1992

    Google Scholar 

  7. Ashby LS, Shapiro WR: Intra-arterial cisplatin plus oral etoposide for the treatment of recurrent malignant glioma: a phase II study. J Neuro-Oncol 51: 67-86, 2001

    Google Scholar 

  8. Schuller E, Seidl R, Wandl C, Dieckmann K, Slavc I: Prolonged second response to cisplatin, etoposide, and ifosfamide in a child with a recurrent brainstem glioblastoma. Pediatr Hematol Oncol 18: 253-258, 2001

    Google Scholar 

  9. Boiardi A, Silvani A, Milanesi I, Broggi G, Fariselli L: Efficacy of ‘8-drugs-in-one-day’ combination in treatment of recurrent GBM patients. J Neuro-Oncol 12: 153-158, 1992

    Google Scholar 

  10. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277-1280, 1990

    Google Scholar 

  11. Kaplan EL, Meyer P: Non parametric estimation for incomplete observation. J Am Stat Assoc 53: 457-481, 1958

    Google Scholar 

  12. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17: 2572-2578, 1999

    Google Scholar 

  13. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343: 1350-1354, 2000

    Google Scholar 

  14. Gerson SL: Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 20: 2388-2399, 2002

    Google Scholar 

  15. Brandes AA, Turazzi S, Basso U, Pasetto LM, Guglielmi B, Volpin L, Ruzzolino P, Amista P, Pinna G, Scienza R, Ermani M: A multidrug combination designed for reversing resistance to BCNU in glioblastoma multiforme. Neurology 58: 1759-1664, 2002

    Google Scholar 

  16. Boiardi A, Silvani A, Ciusani E, Watson A, Margison G, Berger E, Lucas C, Giroux B: Fotemustine combined with procarbazine in recurrent malignant gliomas: a phase I study with evaluation of lymphocyte O6-alkylguanine-DNA alkyltransferase activity. J Neuro-Oncol 52: 149-156, 2001

    Google Scholar 

  17. Quinn JA, Pluda J, Dolan ME, Delaney S, Kaplan R, Rich JN, Friedman AH, Reardon DA, Sampson JH, Colvin OM, Haglund MM, Pegg AE, Moschel RC, McLendon RE, Provenzale JM, Gururangan S, Tourt-Uhlig S, Herndon JE 2nd, Bigner DD, Friedman HS: Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol 20: 2277-2283, 2002

    Google Scholar 

  18. Britten CD, Rowinsky EK, Baker SD, Agarwala SS, Eckardt JR, Barrington R, Diab SG, Hammond LA, Johnson T, Villalona-Calero M, Fraass U, Statkevich P, Von Hoff DD, Eckhardt SG: Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. Clin Cancer Res 5: 1629-1637, 1999

    Google Scholar 

  19. D'Atri S, Graziani G, Lacal PM, Nistico V, Gilberti S, Faraoni I, Watson AJ, Bonmassar E, Margison GP: Attenuation of O(6)-methylguanine-DNA methyltransferase activity and mRNA levels by cisplatin and temozolomide in jurkat cells. J Pharmacol Exp Ther 294: 664-671, 2000

    Google Scholar 

  20. Osoba D, Brada M, Yung WK, Prados M: Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol 18: 1481-1491, 2000

    Google Scholar 

  21. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83: 588-593, 2000

    Google Scholar 

  22. Chinot OL, Honore S, Dufour H, Barrie M, Figarella-Branger D, Muracciole X, Braguer D, Martin PM, Grisoli F: Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 19: 2449-2455, 2001

    Google Scholar 

  23. Brandes AA, Ermani M, Basso U, Paris MK, Lumachi F, Berti F, Amista P, Gardiman, M, Iuzzolino P, Turazzi S, Monfardini S: Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study. Oncology 63: 38-41, 2002

    Google Scholar 

  24. Khan RB, Raizer JJ, Malkin MG, Bazylewicz KA, Abrey LE: A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro-Oncology 4: 39-43, 2002

    Google Scholar 

  25. Trent S, Kong A, Short SC, Traish D, Ashley S, Dowe A, Hines F, Brada M: Temozolomide as second-line chemotherapy for relapsed gliomas. J Neuro-Oncol 57: 247-251, 2002

    Google Scholar 

  26. Groves MD, Puduvalli VK, Hess KR, Jaeckle KA, Peterson P, Yung WK, Levin VA: Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol 20: 1383-1388, 2002

    Google Scholar 

  27. Schold Jr S, Kuhn J, Chang SM, Bosik ME, Robins HI, Mehta MP, Spence AM, Fulton D, Fink KL, Prados MD: A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a North American Brain Tumor Consortium study. Neuro-Oncology 2: 34-39, 2000

    Google Scholar 

  28. Gander M, Leyvraz S, Decosterd L, Bonfanti M, Marzolini C, Shen F, Lienard D, Perey L, Colella G, Biollaz J, Lejeune F, Yarosh D, Belanich M, D'Incalci M: Sequential administration of temozolomide and fotemustine: depletion of O6-alkylguanine-DNA transferase in blood lymphocytes and in tumours. Ann Oncol 10: 831-838, 1999

    Google Scholar 

  29. Stupp R, Gander M, Leyvarz S, Newlands E: Current and future developments in the use of temozolomide for the treatment of brain tumors. Lancet Oncol 2: 552-560, 2001

    Google Scholar 

  30. Houghton PJ, Stewart CF, Cheshire PJ, Richmond LB, Kirstein MN, Poquette CA, Tan M, Friedman HS, Brent TP: Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. Clin Cancer Res 6: 4110-4118, 2000

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Silvani, A., Eoli, M., Salmaggi, A. et al. Phase II Trial of Cisplatin Plus Temozolomide, in Recurrent and Progressive Malignant Glioma Patients. J Neurooncol 66, 203–208 (2004). https://doi.org/10.1023/B:NEON.0000013479.64348.69

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:NEON.0000013479.64348.69

Navigation